A Phase 2 interventional study of Idelalisib and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Gilead Sciences. Terminated at 6 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 11 in phase 2, and was the 3rd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 13th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2010, is one of 9 in phase 2, and was the 9th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety and clinical activity of idelalisib alone and in combination with rituximab in patients with CLL or SLL.
This Phase 2 study will be the first time that idelalisib is administered to previously untreated patients with hematologic malignancies. Idelalisib has demonstrated clinical activity as a single agent in relapsed or refractory CLL and SLL with acceptable toxicity, which supports its evaluation in previously untreated patients. The study population is limited to patients over 65 years of age because younger patients are generally appropriate for standard immunochemotherapy regimens that are highly active. Since the mechanism of action of idelalisib is distinct from rituximab, it is hypothesized that the combination will be more active than either agent alone. This study will establish initial safety and clinical activity of idelalisib in combination with rituximab in patients with CLL or SLL. Cohort 2 of this study will establish safety and clinical activity of idelalisib alone in subjects with untreated CLL or SLL.
Key Inclusion Criteria:
CLL - Binet Stage C or Rai Stage III or IV or has active disease defined by meeting at least one of the following criteria:
At least one of the following disease-related symptoms:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.
Drug: Idelalisib · Drug: Rituximab
Idelalisib 150 mg tablets administered orally twice daily
Also known as: Zydelig®, GS-1101, CAL-101
Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks
Also known as: Rituxan
Overall Response Rate (ORR)
ORR was assessed based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria as specifically modified for this study to reflect current recommendations which consider the mechanism of action of idelalisib and similar drugs, and was defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as assessed by the investigator. Based on the CLL response definition in the protocol (modified Hallek 2008), the parameters of lymphadenopathy, liver and/or spleen size, constitutional symptoms, polymorphonuclear leukocytes, circulating clonal B-lymphocytes, platelet count, hemoglobin, and marrow were assessed. * CR: meeting all defined criteria * PR: meeting at least 2 of the criteria of circulating lymphocytes, lymphadenopathy, liver, spleen, or bone marrow (or only lymphadenopathy if liver and spleen normal at baseline) and at least 1 of the criteria for polymorphonuclear leukocytes, platelet count, or hemoglobin.
Time frame: Up to 28 Months
Overall Safety of Idelalisib
The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).
Time frame: Up to 28 Months
Lymphadenopathy Response Rate
Lymphadenopathy response rate was defined as the percentage of participants with a ≥ 50% reduction from baseline in the sum of the perpendicular diameters of all measurable lesions while receiving study therapy.
Time frame: Baseline and up to 28 Months
Percent Change From Baseline in the Sum of the Product of the Greatest Perpendicular Diameters (SPD) of All Measurable Lesions
Time frame: Baseline; Weeks 8, 16, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Duration of Response
Duration of response (DOR) was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of disease progression or death from any cause.
Time frame: Up to 28 Months
Progression-Free Survival
Progression-free survival (PFS) was defined as the interval from the first dose date of drug to the earlier of the first documentation of definitive disease progression or death from any cause. Progression was defined using the Standardized IWCLL criteria as specifically modified for this study to consider the mechanism of action of idelalisib and similar drugs. The occurrence of any of the following events indicated progression: 1. Evidence of any new disease 2. Evidence of worsening of index lesions, spleen or liver, or non-index disease 3. Decrease in platelet count or hemoglobin that is attributable to CLL and is confirmed by bone marrow biopsy
Time frame: Up to 28 Months
Idelalisib Plasma Concentrations (Cohort 1)
Time frame: Predose and 1.5 hours postdose at Weeks 0, 4, and 24
Idelalisib Plasma Concentrations (Cohort 2)
Time frame: Predose and 1.5 hours postdose at Weeks 0 and 4 and predose at Weeks 8 and 20
Changes in Potential Pharmacodynamic Markers of Drug Activity in Plasma and Whole Blood
Changes in potential pharmacodynamic markers of drug activity will include assessments of chemokine and cytokine concentrations, effects on the activity of PI3K and related pathways, and effect on cell migration and other functional outcomes. This endpoint will be assessed at the following time points: * Idelalisib+Rituximab (Cohort 1): Predose and 1.5 hour postdose on Day 1 and predose on Days 15, 29, 57, 113, and 169 * Idelalisib (Cohort 2): Predose on Days 1, 29, 57, 141
Time frame: Up to 169 days
Overall Survival
Overall survival (OS) is defined as the interval from the start of study treatment to death from any cause.
Time frame: Up to 28 Months
Participants were enrolled at study sites in the United States. The first participant was screened on 28 September 2010. The last study visit occurred on 07 June 2016.
| Milestone | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| Started | 64 | 41 |
| Completed | 43 | 0 |
| Not completed | 21 | 41 |
| Withdrew: Disease progression | 0 | 4 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Withdrew consent | 1 | 10 |
| Withdrew: Investigator request | 0 | 8 |
| Withdrew: Study terminated by sponsor | 0 | 12 |
| Withdrew: Poor tolerance of study drug | 0 | 1 |
| Withdrew: Adverse event | 17 | 5 |
ORR was assessed based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria as specifically modified for this study to reflect current recommendations which consider the mechanism of action of idelalisib and similar drugs, and was defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as assessed by the investigator. Based on the CLL response definition in the protocol (modified Hallek 2008), the parameters of lymphadenopathy, liver and/or spleen size, constitutional symptoms, polymorphonuclear leukocytes, circulating clonal B-lymphocytes, platelet count, hemoglobin, and marrow were assessed. * CR: meeting all defined criteria * PR: meeting at least 2 of the criteria of circulating lymphocytes, lymphadenopathy, liver, spleen, or bone marrow (or only lymphadenopathy if liver and spleen normal at baseline) and at least 1 of the criteria for polymorphonuclear leukocytes, platelet count, or hemoglobin.
| percentage of participants | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| Overall Response Rate (ORR) | 96.9 (89.2 to 99.6) | 87.8 (73.8 to 95.9) |
The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).
| percentage of participants | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| Any AE | 100.0 | 100.0 |
| Serious AE | 48.4 | 68.3 |
| Grade ≥ 3 AE | 76.6 | 85.4 |
| AE related to idelalisib | 81.3 | 97.6 |
| AE leading to permanent drug discontinuation | 28.1 | 56.1 |
Lymphadenopathy response rate was defined as the percentage of participants with a ≥ 50% reduction from baseline in the sum of the perpendicular diameters of all measurable lesions while receiving study therapy.
| percentage of participants | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| Lymphadenopathy Response Rate | 98.0 (89.4 to 99.9) | 86.8 (71.9 to 95.6) |
| percent change | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| % Change at Wk 8 | -100.0 (-100.0 to -8.3) | -69.8 (-100.0 to 0.0) |
| % Change at Wk 16 | -100.0 (-100.0 to -69.2) | -74.5 (-100.0 to 0.0) |
| % Change at Wk 24 | -100.0 (-100.0 to -50.0) | -76.0 (-100.0 to 0.0) |
| % Change at Wk 36 | -100.0 (-100.0 to -66.7) | -77.5 (-100.0 to 0.0) |
| % Change at Wk 48 | -100.0 (-100.0 to -50.0) | -73.9 (-98.3 to 44.4) |
| % Change at Wk 60 | — | -69.7 (-93.3 to -56.7) |
| % Change at Wk 72 | — | -78.0 (-85.5 to -68.8) |
| % Change at Wk 84 | — | -80.0 (-91.2 to -68.1) |
| % Change at Wk 96 | — | -81.3 (-100.0 to -62.5) |
| % Change at Wk 108 | — | -78.1 (-78.1 to -78.1) |
| % Change at Wk 120 | — | -71.9 (-71.9 to -71.9) |
| Best % Change | -100.0 (-100.0 to -40.0) | -81.1 (-100.0 to 0.0) |
Duration of response (DOR) was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of disease progression or death from any cause.
| months | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| Duration of Response | NA (NA to NA) | 14.8 (10.0 to NA) |
Progression-free survival (PFS) was defined as the interval from the first dose date of drug to the earlier of the first documentation of definitive disease progression or death from any cause. Progression was defined using the Standardized IWCLL criteria as specifically modified for this study to consider the mechanism of action of idelalisib and similar drugs. The occurrence of any of the following events indicated progression: 1. Evidence of any new disease 2. Evidence of worsening of index lesions, spleen or liver, or non-index disease 3. Decrease in platelet count or hemoglobin that is attributable to CLL and is confirmed by bone marrow biopsy
| months | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| Progression-Free Survival | NA (NA to NA) | 26.2 (14.0 to NA) |
| ng/mL | Idelalisib+Rituximab (Cohort 1) |
|---|---|
| Week 0 predose | 0.0 (0.0 to 0.0) |
| Week 0 postdose | 1710.0 (1060.0 to 2660.0) |
| Week 4 predose | 305.0 (189.0 to 606.0) |
| Week 4 postdose | 1720.0 (1090.0 to 2500.0) |
| Week 24 predose | 256.5 (173.5 to 625.5) |
| Week 24 postdose | 1460.0 (925.0 to 2010.0) |
| ng/mL | Idelalisib (Cohort 2) |
|---|---|
| Week 0 predose | 0.0 (0.0 to 0.0) |
| Week 0 postdose | 2190.0 (1575.0 to 2920.0) |
| Week 4 predose | 293.0 (228.0 to 549.0) |
| Week 4 postdose | 2120.0 (1850.0 to 2590.0) |
| Week 8 predose | 453.0 (207.0 to 904.0) |
| Week 20 predose | 590.0 (317.0 to 971.5) |
Changes in potential pharmacodynamic markers of drug activity will include assessments of chemokine and cytokine concentrations, effects on the activity of PI3K and related pathways, and effect on cell migration and other functional outcomes. This endpoint will be assessed at the following time points: * Idelalisib+Rituximab (Cohort 1): Predose and 1.5 hour postdose on Day 1 and predose on Days 15, 29, 57, 113, and 169 * Idelalisib (Cohort 2): Predose on Days 1, 29, 57, 141
No measurements were reported for this outcome.
Overall survival (OS) is defined as the interval from the start of study treatment to death from any cause.
No measurements were reported for this outcome.
Collected over Up to 28 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Idelalisib+Rituximab (Cohort 1) | — | 31/64 (48.4%) | 63/64 (98.4%) |
| Idelalisib (Cohort 2) | — | 28/41 (68.3%) | 40/41 (97.6%) |
| Event | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/64 | 7/41 |
| PneumoniaInfections and infestations | 8/64 | 5/41 |
| ColitisGastrointestinal disorders | 6/64 | 4/41 |
| PyrexiaGeneral disorders | 2/64 | 3/41 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/64 | 2/41 |
| CellulitisInfections and infestations | 1/64 | 2/41 |
| DehydrationMetabolism and nutrition disorders | 1/64 | 2/41 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/64 | 2/41 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/64 | 2/41 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/64 | 1/41 |
| Event | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 31/64 | 27/41 |
| PyrexiaGeneral disorders | 26/64 | 13/41 |
| NauseaGastrointestinal disorders | 24/64 | 14/41 |
| RashSkin and subcutaneous tissue disorders | 24/64 | 14/41 |
| ChillsGeneral disorders | 23/64 | 6/41 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/64 | 11/41 |
| FatigueGeneral disorders | 20/64 | 13/41 |
| ConstipationGastrointestinal disorders | 11/64 | 12/41 |
| Alanine aminotransferase increasedInvestigations | 18/64 | 11/41 |
| Upper respiratory tract infectionInfections and infestations | 7/64 | 11/41 |
Intent-to-treat (ITT) Analysis Set: participants who received at least 1 dose of idelalisib.
| Age, Customized(participants) | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) | Total |
|---|---|---|---|
| < 70 Years | 29 | 14 | 43 |
| ≥ 70 Years | 35 | 27 | 62 |
| Sex: Female, Male(Participants) | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) | Total |
|---|---|---|---|
| Female | 24 | 9 | 33 |
| Male | 40 | 32 | 72 |
| Ethnicity (NIH/OMB)(Participants) | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 64 | 40 | 104 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Idelalisib+Rituximab (Cohort 1) | Idelalisib (Cohort 2) | Total |
|---|---|---|---|
| White/Caucasian | 61 | 40 | 101 |
| Black or African American | 1 | 1 | 2 |
| Asian | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Oct 2010 to primary completion in Aug 2015, 58 months.
Results were first posted in May 2017, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →